drugset / Trial / NCT04493333
Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
RandomizedParallel-groupSingle-blindSupportive care
Summary
The purpose of this research is to gather information on the safety and effectiveness of Intrarosa®, also known as Dehydroepiandrosterone (DHEA), and prasterone. By doing this study, the investigators hope to learn if Intrarosa® can improve vaginal discomfort. Participants will be assigned to one of two groups. One group will use Intrarosa® once a day. The other group will use Replens™ two times a week.
Timeline
- Start
- 2021-06-07
- Primary completion
- 2023-07-18
- Completion
- 2023-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dehydroepiandrosterone | Other / unclassified | 6.5 mg | Other |
| Subject | polycarbophil | Small molecule | 2.5 g | Other |